Short Bowel Syndrome (SBS) is a rare, chronic malabsorption disorder resulting from extensive surgical resection of the small intestine (often due to Crohn’s disease, mesenteric ischemia, volvulus, trauma, or congenital defects). It leads to severe diarrhea, malnutrition, dehydration, electrolyte imbalances, and dependence on long-term parenteral nutrition (PN). The global SBS drugs market includes specialized pharmacological therapies aimed at reducing PN dependence, improving intestinal adaptation, enhancing nutrient absorption, and managing complications. Key drug classes include glucagon-like peptide-2 (GLP-2) analogs, growth hormone therapies, and emerging oral/anti-diarrheal agents. The market is characterized by orphan drug status, high unmet need, limited competition, and very high per-patient treatment cost. North America dominates (largest share) due to early access to teduglutide (Gattex/Revestive), strong orphan drug incentives, advanced PN infrastructure, and high diagnosis rates, while Europe grows fastest from expanding reimbursement for teduglutide and increasing awareness in key countries.

Market Size and Growth Projections

The global short bowel syndrome drugs market was valued at USD 1.12 billion in 2024 and is projected to reach USD 2.89 billion by 2032, growing at a compound annual growth rate (CAGR) of 12.6% during the forecast period from 2025 to 2032. This strong growth is driven by increasing diagnosis rates, longer life expectancy of SBS patients, expansion of GLP-2 analog access, and promising late-stage pipeline candidates.

Market Segmentation

The market is segmented as follows:

• By Drug Class: GLP-2 Analogs (teduglutide – dominant share in 2025; Gattex/Revestive is currently the only approved product), Growth Hormone Therapies (somatropin – still significant), Anti-Diarrheal & Anti-Secretory Agents (fastest-growing segment; emerging oral therapies), Others.
• By Route of Administration: Parenteral/Injectable (dominant; nearly all current therapies), Oral (fastest-growing; major focus of pipeline candidates).
• By Patient Type: Adult SBS Patients (largest share), Pediatric SBS Patients (fastest-growing due to increasing congenital cases and long-term survival).
• By Distribution Channel: Hospital Pharmacies (dominant), Specialty Pharmacies (fastest-growing; critical for high-cost orphan drugs), Retail Pharmacies, Online Pharmacies.
• By Region: North America (largest revenue share; U.S. & Canada early access to teduglutide), Europe (fastest-growing; reimbursement expansion in Germany, UK, France, Italy), Asia-Pacific, Latin America, Middle East & Africa.

Key Drivers Fueling Growth

• Rising incidence of intestinal resections due to Crohn’s disease, vascular events, and trauma.
• Increasing survival rates of SBS patients leading to longer-term treatment needs.
• Proven efficacy of GLP-2 analogs (teduglutide) in significantly reducing parenteral nutrition dependence.
• Strong orphan drug incentives, fast-track designations, and premium pricing support.
• Growing awareness among gastroenterologists and improved diagnosis rates.
• Robust late-stage pipeline of next-generation GLP-2 analogs and oral therapies.

Challenges and Restraints

• Extremely high cost of therapy (teduglutide annual cost often >USD 200,000–400,000 per patient).
• Limited reimbursement and access barriers in many countries.
• Requirement for long-term subcutaneous injections and close monitoring.
• Side effects (abdominal pain, injection site reactions, potential colorectal neoplasia risk).
• Very small patient population (orphan indication) limits commercial scale.

Get Full Access Of The Report: https://www.databridgemarketresearch.com/reports/global-short-bowel-syndrome-drugs-market

Opportunities

• Launch and geographic expansion of next-generation GLP-2 analogs with improved dosing or efficacy.
• Development of first oral therapies that could dramatically expand the market.
• Increasing reimbursement and access programs in Europe and select Asia-Pacific markets.
• Combination therapies and personalized treatment approaches.
• Growth in pediatric SBS population requiring long-term management.
• Potential label expansion for existing therapies (e.g., pediatric use, additional indications).

Competitive Landscape

The current market is highly concentrated with only one approved product (teduglutide – Takeda/NPS Pharmaceuticals), but the pipeline is active with several companies developing next-generation GLP-2 analogs and oral therapies. Key players include:

• Takeda Pharmaceutical Company Limited (Gattex/Revestive – market leader)
• Ironwood Pharmaceuticals (linaclotide – exploratory)
• 9 Meters Biopharma (larazotide – historical interest)
• Hanmi Pharmaceutical (HM11260C – next-gen GLP-2)
• Zealand Pharma (glepaglutide – Phase 3, most advanced pipeline candidate)
• PhaseBio Pharmaceuticals (historical)
• Others (early-stage biotech companies focusing on oral SBS therapies)

Future Trends and Opportunities

Trends include shift toward longer-acting GLP-2 analogs (weekly/bi-weekly dosing), development of first oral therapies, improved patient-reported outcomes, real-world evidence generation for PN reduction, and potential combination with anti-diarrheal agents. Opportunities are strongest in European reimbursement expansion, pediatric population growth, and launch of more convenient next-generation therapies.

Conclusion

The global short bowel syndrome drugs market is positioned for strong, double-digit growth through 2032, driven by increasing diagnosis, proven benefit of GLP-2 analogs, and promising oral pipeline candidates—led by North America and fastest-growing in Europe. While extremely high costs and limited patient numbers remain challenges, the orphan status, premium pricing, and transformative impact on quality of life offer substantial commercial potential. Stakeholders should closely monitor late-stage pipeline readouts (especially glepaglutide) and geographic reimbursement expansions to capitalize on this high-value rare disease market.

Browse More Reports:

Global Payment Gateway Market

Global Imitation Jewellery Market

Global Industrial Cybersecurity Market

Global Beauty Devices Market

Global Matcha Tea Market

Global AI Meeting Assistants Market

Global Air Fryer Market

Global Dengue Vaccine Market

Global Insulin Market

Global Biscuits Market

Global Predictive Maintenance Market

Global Vetiver Oil Market

Global Underwater Robotics Market

Global Aloe Vera Market

Global Xylitol Market

About Data Bridge Market Research:

An absolute way to forecast what the future holds is to comprehend the trend today! Data Bridge Market Research set forth itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us:

Data Bridge Market Research US: +1 614 591 3140 UK: +44 845 154 9652 APAC : +653 1251 975 Email:- corporatesales@databridgemarketresearch.com